Open Label Doxycycline Injection for Neurofibromatosis Type 2

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Massachusetts Eye and Ear, Boston, MA
Neurofibromatosis Type 2+5 More
Doxycycline Injection [Doxy] - Drug
Eligibility
Any Age
All Sexes
What conditions do you have?
Select

Study Summary

In this research study the investigators want to learn more about an alternate, local treatment for skin schwannomas. Specifically, local doxycycline intra-tumoral injection will be performed as a potential treatment for NF2-related skin schwannomas, ultimately reducing the risks and costs associated with standard surgical removal of such skin tumors if successful.

Eligible Conditions

  • Neurofibromatosis Type 2

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Neurofibromatosis Type 2

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 6-months, 1-year

6-months, 1-year
Tumor Maximal Diameter

Trial Safety

Safety Progress

1 of 3

Other trials for Neurofibromatosis Type 2

Trial Design

2 Treatment Groups

Open Label Doxycycline Injection
1 of 2
Single Arm Open Label
1 of 2
Experimental Treatment

19 Total Participants · 2 Treatment Groups

Primary Treatment: Open Label Doxycycline Injection · No Placebo Group · Phase 1 & 2

Open Label Doxycycline Injection
Drug
Experimental Group · 1 Intervention: Doxycycline Injection [Doxy] · Intervention Types: Drug
Single Arm Open Label
Drug
Experimental Group · 1 Intervention: Doxycycline Injection [Doxy] · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 6-months, 1-year

Trial Background

Prof. D. Bradley Welling,, MD PhD
Principal Investigator
Massachusetts Eye and Ear Infirmary
Closest Location: Massachusetts Eye and Ear · Boston, MA
Photo of Boston  1Photo of Boston  2Photo of Boston  3
2019First Recorded Clinical Trial
2 TrialsResearching Neurofibromatosis Type 2
8 CompletedClinical Trials

Eligibility Criteria

Age Any Age · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a tumor that is larger than 0.5 cm to less than 4.0 cm.
You are fully recovered from acute toxic effects of any prior chemotherapy, biological modifiers or radiotherapy.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References